RAJAF — Cordyceps Sunshine Biotech Holdings Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid Cap

Market Cap
$1.02bn
Enterprise Value
$1.02bn
Revenue
$1.25m

Annual cashflow statement for Cordyceps Sunshine Biotech Holdings Co, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS/A	PROSPECTUS/A	20-F	20-F	20-F
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-0.013	-0.491	-0.72	0.169	-0.226
Depreciation
Amortisation
Non-Cash Items	0	0.386	0.086	0.152	0.103
Discontinued Operations
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-0.146	-0.419	0.085	-0.019	0.011
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Cash from Operating Activities	-0.131	-0.365	-0.321	0.36	0.312
Capital Expenditures	-1.11	-0.111	-0	-0.319	-0.349
Purchase of Fixed Assets
Other Investing Cash Flow Items	-0.389	—	—	-0	0.044
Sale of Fixed Assets
Other Investing Cash Flow
Cash from Investing Activities	-1.5	-0.111	-0	-0.32	-0.306
Financing Cash Flow Items	1.22	0.342	0.246	-0.032	0
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	1.63	0.575	0.246	-0.032	0
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	0	0.099	-0.084	0.007	0.014